Radiomic and Volumetric Measurements as Clinical Trial Endpoints—A Comprehensive Review

Ionut-Gabriel Funingana, Pubudu Piyatissa, Marika Reinius, Cathal Mccague, Bristi Basu, Evis Sala

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Simple Summary The extraction of quantitative data from standard-of-care imaging modalities offers opportunities to improve the relevance and salience of imaging biomarkers used in drug development. This review aims to identify the challenges and opportunities for discovering new imaging-based biomarkers based on radiomic and volumetric assessment in the single-site solid tumor sites: breast cancer, rectal cancer, lung cancer and glioblastoma. Developing approaches to harmonize three essential areas: segmentation, validation and data sharing may expedite regulatory approval and adoption of novel cancer imaging biomarkers. Clinical trials for oncology drug development have long relied on surrogate outcome biomarkers that assess changes in tumor burden to accelerate drug registration (i.e., Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria). Drug-induced reduction in tumor size represents an imperfect surrogate marker for drug activity and yet a radiologically determined objective response rate is a widely used endpoint for Phase 2 trials. With the addition of therapies targeting complex biological systems such as immune system and DNA damage repair pathways, incorporation of integrative response and outcome biomarkers may add more predictive value. We performed a review of the relevant literature in four representative tumor types (breast cancer, rectal cancer, lung cancer and glioblastoma) to assess the preparedness of volumetric and radiomics metrics as clinical trial endpoints. We identified three key areas-segmentation, validation and data sharing strategies-where concerted efforts are required to enable progress of volumetric- and radiomics-based clinical trial endpoints for wider clinical implementation.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
RivistaCancers
Volume14
DOI
Stato di pubblicazionePubblicato - 2022

Keywords

  • clinical trials
  • data integration
  • imaging biomarkers
  • radiomics
  • surrogate endpoints
  • volumetric

Fingerprint

Entra nei temi di ricerca di 'Radiomic and Volumetric Measurements as Clinical Trial Endpoints—A Comprehensive Review'. Insieme formano una fingerprint unica.

Cita questo